EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeutics

Nevena V Radonjić, Khatiya C Moon, Kristina M Deligiannidis

Journal of Neuroendocrinology · 2026

DOI: 10.1111/jne.70253 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Neuroendocrinology, 2026. Verfasst von Nevena V Radonjić und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA. Hauptthemen laut MEDLINE: Depression, Postpartum, Neurosteroids, Precision Medicine, Pregnanediones. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, Brain and Behavior Research Foundation, New York State Department of Health Empire Clinical Research Investigator Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurosteroids and their role in the pathophysiology of perinatal depression have been in the focus of scientific investigation for several decades. Recently, two synthetic analogs of the neurosteroid allopregnanolone—brexanolone and zuranolone—received approval in the United States for the treatment of postpartum depression (PPD) exhibiting a rapid, long‐lasting antidepressant effect through a novel mechanism of action. These developments mark a milestone in psychiatric research and advancement in available treatment options. In this review, we examine the role of neurosteroids in perinatal depression, with particular emphasis on their impact on network states and functional connectivity. We synthesize current clinical experience with brexanolone and zuranolone in the treatment of PPD, highlighting efficacy and practical considerations. Finally, we explore emerging precision medicine approaches that leverage the heterogeneity of clinical presentations and treatment responses in PPD to guide the development of targeted therapeutic strategies for this widely prevalent and debilitating condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Depression, PostpartumNeurosteroidsPrecision MedicinePregnanedionesHumansFemaleAnimalsPregnancyAntidepressive AgentsPregnanoloneDrug CombinationsPyrazolesbeta-Cyclodextrins

Stichwörter der Autor:innen

antidepressantneurosteroidperipartum depressionpostpartum depressionzuranolone

Substanzen

NeurosteroidsbrexanolonezuranoloneAntidepressive AgentsPregnanolonePregnanedionesDrug CombinationsPyrazolesbeta-Cyclodextrins

Autor:innen und Institutionen

  • Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, SUNY Upstate Medical University, Syracuse, New York, USA.
  • Northwell Health, New Hyde Park, New York, USA.
  • Institute of Behavioral Science, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, New York, USA.

Förderung

  • NIMH NIH HHS
  • Brain and Behavior Research Foundation
  • New York State Department of Health Empire Clinical Research Investigator Program
  • National Institute of Mental Health
  • New York State Department of Health

Zitieren

APA

Radonjić, N. V., Moon, K. C., & Deligiannidis, K. M. (2026). The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeutics. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.70253

Vancouver

Radonjić NV, Moon KC, Deligiannidis KM. The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeutics. Journal of Neuroendocrinology. 2026. doi:10.1111/jne.70253

BibTeX
@article{Radonji2026,
  author = {Radonjić, Nevena V and Moon, Khatiya C and Deligiannidis, Kristina M},
  title = {The neurosteroid paradigm in perinatal depression: From pathophysiology to precision therapeutics},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  doi = {10.1111/jne.70253}
}
Kostenlos starten →